These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32613795)

  • 1. Modeling in Early Stages of Technology Development: Is an Iterative Approach Needed? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Drummond MF
    Int J Health Policy Manag; 2020 Jun; 9(6):260-262. PubMed ID: 32613795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming Disciplinary Traditions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Lehoux P; Silva H
    Int J Health Policy Manag; 2020 Jul; 9(7):309-311. PubMed ID: 32613802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement Decision-Making Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Kim H; Goodall S; Liew D
    Int J Health Policy Manag; 2021 Feb; 10(2):98-101. PubMed ID: 32610777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Health Economic Modelling - Optimizing Development for Medical Device Developers? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Teljeur C; Ryan M
    Int J Health Policy Manag; 2020 Sep; 9(9):403-405. PubMed ID: 32610765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the Role of Early Health Economic Modelling in Evaluation of Health Technologies Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Federici C; Torbica A
    Int J Health Policy Manag; 2021 Feb; 10(2):102-105. PubMed ID: 32610778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling.
    Grutters JPC; Govers T; Nijboer J; Tummers M; van der Wilt GJ; Rovers MM
    Int J Health Policy Manag; 2019 Oct; 8(10):575-582. PubMed ID: 31657184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling".
    Zawadzki NK; Hay JW
    Int J Health Policy Manag; 2020 Aug; 9(8):352-355. PubMed ID: 32613807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. It's Not the Model, It's the Way You Use It: Exploratory Early Health Economics Amid Complexity Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling".
    Partington A; Karnon J
    Int J Health Policy Manag; 2021 Jan; 10(1):36-38. PubMed ID: 32610772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Useful Are Early Economic Models? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling".
    Love-Koh J
    Int J Health Policy Manag; 2020 May; 9(5):215-217. PubMed ID: 32563224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Price of Substitute Technologies.
    Santos AS; Guerra-Junior AA; Noronha KVMS; Andrade MV; Ruas CM
    Value Health Reg Issues; 2019 Dec; 20():154-158. PubMed ID: 31561148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.
    IJzerman MJ; Koffijberg H; Fenwick E; Krahn M
    Pharmacoeconomics; 2017 Jul; 35(7):727-740. PubMed ID: 28432642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating Real Option Value in Valuing Innovation: A Way Forward.
    Li M; Garrison LP
    Pharmacoeconomics; 2024 Jul; 42(Suppl 2):199-210. PubMed ID: 38310635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Conceptualization of Value in the Value Proposition of New Health Technologies Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".
    Buttigieg SC; Hoof JV
    Int J Health Policy Manag; 2018 Feb; 7(2):186-188. PubMed ID: 29524943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Economic Evaluation of Diagnostic Technologies: Experiences of the NIHR Diagnostic Evidence Co-operatives.
    Abel L; Shinkins B; Smith A; Sutton AJ; Sagoo GS; Uchegbu I; Allen AJ; Graziadio S; Moloney E; Yang Y; Hall P
    Med Decis Making; 2019 Oct; 39(7):857-866. PubMed ID: 31556806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spanish recommendations on economic evaluation of health technologies.
    López-Bastida J; Oliva J; Antoñanzas F; García-Altés A; Gisbert R; Mar J; Puig-Junoy J
    Eur J Health Econ; 2010 Oct; 11(5):513-20. PubMed ID: 20405159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of economic evaluation in the pricing and reimbursement of medicines.
    Drummond M; Jönsson B; Rutten F
    Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices.
    Grimm SE; Dixon S; Stevens JW
    Value Health; 2016; 19(6):720-726. PubMed ID: 27712696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing role of economic evaluation in valuing medical technologies.
    Rotter JS; Foerster D; Bridges JF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):711-23. PubMed ID: 23252354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.